ATE252639T1 - Modifizierter, das dorsalgewebe beeinflussender faktor - Google Patents

Modifizierter, das dorsalgewebe beeinflussender faktor

Info

Publication number
ATE252639T1
ATE252639T1 AT98936850T AT98936850T ATE252639T1 AT E252639 T1 ATE252639 T1 AT E252639T1 AT 98936850 T AT98936850 T AT 98936850T AT 98936850 T AT98936850 T AT 98936850T AT E252639 T1 ATE252639 T1 AT E252639T1
Authority
AT
Austria
Prior art keywords
factor affecting
modified factor
dorsal tissue
muteins
dorsal
Prior art date
Application number
AT98936850T
Other languages
English (en)
Inventor
Neil Stahl
Richard M Harland
Aris N Economides
Original Assignee
Regeneron Pharma
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Univ California filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE252639T1 publication Critical patent/ATE252639T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98936850T 1997-07-17 1998-07-17 Modifizierter, das dorsalgewebe beeinflussender faktor ATE252639T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/897,236 US6075007A (en) 1997-07-17 1997-07-17 Modified noggin polypeptide and compositions
PCT/US1998/014603 WO1999003996A1 (en) 1997-07-17 1998-07-17 Modified dorsal tissue affecting factor and compositions

Publications (1)

Publication Number Publication Date
ATE252639T1 true ATE252639T1 (de) 2003-11-15

Family

ID=25407592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98936850T ATE252639T1 (de) 1997-07-17 1998-07-17 Modifizierter, das dorsalgewebe beeinflussender faktor

Country Status (9)

Country Link
US (3) US6075007A (de)
EP (1) EP1003860B1 (de)
JP (1) JP4181300B2 (de)
AT (1) ATE252639T1 (de)
AU (1) AU735851B2 (de)
CA (1) CA2296769C (de)
DE (1) DE69819167T2 (de)
IL (2) IL134042A0 (de)
WO (1) WO1999003996A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660499B1 (en) 1998-08-20 2003-12-09 Regeneron Pharmaceuticals, Inc. DCR5, a BMP-binding protein, and applications thereof
DE69933044T3 (de) 1998-11-27 2016-11-24 Ucb Pharma, S.A. Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
AU2002243495A1 (en) * 2001-01-12 2002-07-24 University Of Medicine And Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
US20030134790A1 (en) * 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
WO2003070189A2 (en) * 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
NZ542587A (en) * 2003-03-14 2008-05-30 Celltech R & D Inc Complex comprising a TGF-beta binding protein and a BMP antagonist protein in specific association used to modulate bone mineralization
EP1636270B1 (de) 2003-06-16 2016-07-20 UCB Pharma S.A. Spezifische antikörper für sclerostin und verfahren zur erhöhung der knochenmineralisierung
NZ582597A (en) * 2004-07-09 2011-08-26 Viacyte Inc Preprimitive streak and mesendoderm cells
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
AU2006289667A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US20100272695A1 (en) * 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US20140080153A1 (en) * 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
EP2681242B1 (de) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin- und dkk-1-bispezifische bindemittel
WO2012135035A1 (en) 2011-03-25 2012-10-04 Amgen Inc. Anti - sclerostin antibody crystals and formulations thereof
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CA2842432C (en) 2011-08-04 2022-10-04 Amgen Inc. Method for treating bone gap defects
SG11201403718YA (en) 2011-12-28 2014-07-30 Amgen Inc Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102486321B1 (ko) 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
EP3774879B1 (de) 2018-03-30 2026-01-28 Amgen Inc. C-terminale antikörpervarianten
CN113785052B (zh) * 2019-02-19 2024-06-28 维也纳兽医大学 新重组二胺氧化酶及其治疗以过量组胺为特征的疾病的用途
JP7848994B2 (ja) * 2021-12-28 2026-04-21 国立大学法人山口大学 ノギンタンパク質を分泌する細胞およびそれを用いたオルガノイドの作製方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256568A (en) 1990-02-12 1993-10-26 Regeneron Phamaceuticals, Inc. Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers
DK0550665T3 (da) 1990-09-25 1996-12-02 Genentech Inc Ny neurotrofisk faktor
IL134656A (en) * 1992-09-03 2006-12-10 Univ California Antibodies which bind a noggin polypeptide and hybridoma capable of producing such antibodies
ZA936478B (en) * 1992-09-03 1994-09-30 Regeneron Pharma Dorsal tissue affecting factor and compositions

Also Published As

Publication number Publication date
IL134042A0 (en) 2001-04-30
DE69819167T2 (de) 2004-07-22
CA2296769A1 (en) 1999-01-28
WO1999003996A1 (en) 1999-01-28
AU8570898A (en) 1999-02-10
IL134042A (en) 2006-12-10
EP1003860B1 (de) 2003-10-22
US6075007A (en) 2000-06-13
DE69819167D1 (de) 2003-11-27
JP2001510044A (ja) 2001-07-31
JP4181300B2 (ja) 2008-11-12
CA2296769C (en) 2008-01-15
US20030129703A1 (en) 2003-07-10
AU735851B2 (en) 2001-07-19
HK1026229A1 (en) 2000-12-08
US6500640B1 (en) 2002-12-31
EP1003860A1 (de) 2000-05-31

Similar Documents

Publication Publication Date Title
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
ID26326A (id) Deripat-deripat 2 purin 9 il tetrahiderofuran 3,4 diol
PT1091975E (pt) Nova ciclosporina com um perfil de actividade melhorado
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
IL106894A0 (en) Dorsal tissue affecting factor and compositions
DE69937573D1 (de) Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
WO1999051731A3 (en) Maize histone deacetylases and their use
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
IT1293691B1 (it) Stent per angioplastica, particolarmente per il trattamento di vasi presentanti biforcazioni.
NO986034D0 (no) Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse
HUP0104825A3 (en) Genes and proteins, and their use
ATE291586T1 (de) Humanes antibiotisches protein
IL139604A0 (en) Novel peptides
PE20399A1 (es) Muteina ob
DE69737265D1 (de) Herstellung nickelenthaltenden, gesinterten, verfestigten, feritischen rostfreien stahls
EP1096927A4 (de) Zusammensetzung für stressbehandlung
IT242987Y1 (it) Guarnitura per mobili.
NO20013101D0 (no) Ytre overflateproteiner, deres gener og deres anvendelse
DE10081621D2 (de) Promotorsystem, dessen Herstellung und Verwendung
DE69828906D1 (de) Herstellung von 1,3 propandiolestern
DE69930370D1 (de) Testisspezifische, menschliche proteinase, svph1-8
GB9723824D0 (en) Cytostatic agents
NO179773C (no) Fjernbar, ortopedisk brudd-stabilisator
AP2005003413A0 (en) Genes and proteins, and their use.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1003860

Country of ref document: EP

REN Ceased due to non-payment of the annual fee